Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark A Boyd

Showing results (51-60 of 93) with videos related to

Pageof 10
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|March 17, 2012
A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adultsDianne Carey, Sarah L Pett, Mark Bloch, et al.
AIDS (London, England)|August 8, 2013
Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapyAllison Martin, Cecilia Moore, Patrick W G Mallon, et al.
British Journal of Anaesthesia|November 6, 2024
It is time to take a broader equity lens to highlight health inequalities in people with painEmma L Karran, Aidan G Cashin, Trevor Barker, et al.
Pain|April 21, 2025
Developing consensus on the most important equity-relevant items to include in pain research: a modified e-Delphi studyEmma L Karran, Aidan G Cashin, Trevor Barker, et al.
AIDS (London, England)|May 29, 2004
Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohortW Phillip Law, Chris J Duncombe, Apicha Mahanontharit, et al.
AIDS (London, England)|October 3, 2003
Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001W Phillip Law, Gregory J Dore, Chris J Duncombe, et al.
AIDS Research and Therapy|March 7, 2015
A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infectionStephen G Holt, David M Gracey, Miriam T Levy, et al.
Eclinicalmedicine|November 10, 2025
Identifying Social factors that Stratify Health Opportunities and Outcomes (ISSHOOs) in pain research: consensus recommendations for the collection and reporting of equity-relevant dataEmma L Karran, Aidan G Cashin, Alessandro Chiarotto, et al.
Antiviral Therapy|February 5, 2008
Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimenReshma S Autar, Mark A Boyd, Ferdinand W M N Wit, et al.
Plos One|November 9, 2013
HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapyAllison Martin, Cecilia L Moore, Patrick W G Mallon, et al.
Pageof 10

Showing results (51-60 of 93) with videos related to

Sort By:
Pageof 10
Journal of Acquired Immune Deficiency Syndromes (1999)|March 17, 2012
A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adultsDianne Carey, Sarah L Pett, Mark Bloch, et al.
AIDS (London, England)|August 8, 2013
Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapyAllison Martin, Cecilia Moore, Patrick W G Mallon, et al.
British Journal of Anaesthesia|November 6, 2024
It is time to take a broader equity lens to highlight health inequalities in people with painEmma L Karran, Aidan G Cashin, Trevor Barker, et al.
Pain|April 21, 2025
Developing consensus on the most important equity-relevant items to include in pain research: a modified e-Delphi studyEmma L Karran, Aidan G Cashin, Trevor Barker, et al.
AIDS (London, England)|May 29, 2004
Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohortW Phillip Law, Chris J Duncombe, Apicha Mahanontharit, et al.
AIDS (London, England)|October 3, 2003
Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001W Phillip Law, Gregory J Dore, Chris J Duncombe, et al.
AIDS Research and Therapy|March 7, 2015
A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infectionStephen G Holt, David M Gracey, Miriam T Levy, et al.
Eclinicalmedicine|November 10, 2025
Identifying Social factors that Stratify Health Opportunities and Outcomes (ISSHOOs) in pain research: consensus recommendations for the collection and reporting of equity-relevant dataEmma L Karran, Aidan G Cashin, Alessandro Chiarotto, et al.
Antiviral Therapy|February 5, 2008
Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimenReshma S Autar, Mark A Boyd, Ferdinand W M N Wit, et al.
Plos One|November 9, 2013
HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapyAllison Martin, Cecilia L Moore, Patrick W G Mallon, et al.
Pageof 10